Key result
Statins modulate auto- and allo-immune responses through mevalonate pathway inhibition across multiple immune cells.
Answers are grounded in this paper and cite their sources.
The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.
No takes yet. Share an insight, caveat, or question.
Zeiser et al. (2008) conducted a review in Inflammatory diseases and immune disorders. Statins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) was evaluated. Statins modulate autoantigen and alloantigen-driven immune responses via the mevalonate pathway in a disease-specific manner across multiple immune cell types.
Synapse has enriched 10 related papers. Consider them for comparative context: